Stocklytics Platform
Asset logo for symbol CDTX
Cidara Therapeutics
CDTX60
$23.87arrow_drop_down6.95%-$1.73
Asset logo for symbol CDTX
CDTX60

$23.87

arrow_drop_down6.95%

Performance History

Chart placeholder
Key Stats
Open$24.79
Prev. Close$24.88
EPS-23.90
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range22.34
25.15
52 Week Range10.00
28.35
Ratios
EPS-23.90

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Cidara Therapeutics (CDTX)

Cidara Therapeutics Inc (CDTX) is a biotechnology company focused on the research and development of novel anti-infectives. The company's primary goal is to address the urgent and growing need for new treatments for serious infections caused by drug-resistant pathogens. CDTX is developing a novel approach to the treatment of infections, utilizing its proprietary Cloudbreak(TM) Immunotherapy Platform. This platform is designed to harness the power of the immune system to fight infections and has the potential to revolutionize the treatment of serious infections.
CDTX's lead product candidate is rezafungin acetate, a once-weekly echinocandin antifungal for the treatment and prevention of serious fungal infections. Echinocandins are a class of antifungal agents that inhibit the synthesis of beta(1,3)-D-glucan, an essential component of the fungal cell wall. Rezafungin has demonstrated potent activity against a wide range of clinically-relevant fungal pathogens, including multidrug-resistant strains. The drug has completed a Phase 2 trial for the treatment of candidemia and invasive candidiasis, and is currently in Phase 3 trials.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jeffrey L. Stein Ph.D.
Headquarters
San Diego
Employees
73
Exchange
NASDAQ
add Cidara Therapeutics  to watchlist

Keep an eye on Cidara Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Cidara Therapeutics 's (CDTX) price per share?

The current price per share for Cidara Therapeutics (CDTX) is $23.87. The stock has seen a price change of -$1.73 recently, indicating a -6.95% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Cidara Therapeutics (CDTX)?

For Cidara Therapeutics (CDTX), the 52-week high is $28.36, which is 18.78% from the current price. The 52-week low is $10, the current price is 138.71% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Cidara Therapeutics (CDTX) a growth stock?

Cidara Therapeutics (CDTX) has shown an average price growth of -1.37% over the past three years. It has received a score of 99 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cidara Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Cidara Therapeutics (CDTX) stock price performance year to date (YTD)?

As of the latest data, Cidara Therapeutics (CDTX) has a year-to-date price change of -11.19%. Over the past month, the stock has experienced a price change of 6.05%. Over the last three months, the change has been 120.01%. Over the past six months, the figure is 107.12%. Looking at a longer horizon, the five-year price change stands at -68.59%.
help

Is Cidara Therapeutics (CDTX) a profitable company?

Cidara Therapeutics (CDTX) has a net income of -$22.93M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -3.68K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $63.9M, although specific revenue growth data is currently not available. The gross profit is $62.38M. Operating income is noted at -$24.48M. Furthermore, the EBITDA is -$30.11M.
help

What is the market capitalization of Cidara Therapeutics (CDTX)?

Cidara Therapeutics (CDTX) has a market capitalization of $260.06M. The average daily trading volume is 23.46, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level